Drug Profile
Research programme: biosimilar recombinant human blood factors - Inbiopro Solutions
Alternative Names: IBPB 001OCLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Inbiopro Solutions
- Class Blood coagulation factors; Recombinant proteins
- Mechanism of Action Blood coagulation factor replacements; Factor IXa stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Haemophilia-A in India
- 19 Aug 2013 Preclinical trials in Haemophilia A (treatment and prevention) in India (unspecified route)